Drug Discovery · Saint Louis, MO · Founded 2018 · Privately Held (backing)
Developer of off-the-shelf cell therapy technology designed to treat hematologic and solid tumor cancers. Wugen is based in Saint Louis, MO and was founded in 2018. It is valued at about $215 million as of Oct 2026, set by institutional fund marks, down 12% since its later-stage round in Aug 2025. It has raised $323 million across 2 recorded rounds; the latest was an $115 million Series C in Aug 2025.
PMV mark · valuation
$214.5M
Oct 2026
Since last round
-12%
Aug 2025
Total raised
$323.0M
Last round
Later Stage VC (Series C)
Aug 2025
Team — not yet on record
No current team members for Wugen are on record yet. People surface from round filings, company disclosures, and coverage sessions.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Wugen with a free account
·The complete investor list: 13 names
·Watch Wugen: the Monday email on marks, rounds and moves
